Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

(Reuters) - Eli Lilly's blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound, as well as Novo Nordisk's rival ...

We've got fresh evidence for how weight can quickly be regained after weight-loss programs stop – but rather than looking at ...

When people were randomised to receive either a placebo or Ozempic, they became biologically younger with the latter drug ...

GLP-1 drugs like Ozempic are transforming weight loss, but a new UVA study warns they're not improving a critical measure of ...

The overarching commonality is that there isn't one: "Not all people experiences the same degree of facial and body changes ...

Supplements were also to blame when a 53-year-old woman’s left hand suddenly went numb, according to a case study in the ...

The supermarket has pulled the product from shelves and is urging customers who have already bought it not to eat it.

Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor ...

There's been plenty of buzz about this class of drug, following publication of a high-profile trial this year. How much do we ...

Ozempic and its counterparts, including Wegovy, Mounjaro and Zepbound, have surged in popularity as a means for weight loss, fueled by celebrity endorsements and slick pharmaceutical marketing.

Anti-CGRP monoclonal antibody therapy in patients with migraine can reduce headache burden and stabilize retinal and optic nerve changes.